Estrogen receptor status and response to chemotherapy in advanced breast cancer: the Tufts-Shattuck-Pondville experience

Cancer. 1980 Dec 15;46(12 Suppl):2919-21. doi: 10.1002/1097-0142(19801215)46:12+<2919::aid-cncr2820461434>3.0.co;2-x.

Abstract

Eighty-eight patients with advanced breast cancer were retrospectively reviewed to compare estrogen receptor (ER) data with response to cytotoxic chemotherapy. All assays were done in a single laboratory. All patients were cared for at a single institution. Thirty-four patients were treated with chemotherapy, 30 of whom were evaluable for response by criteria of the Eastern Cooperative Oncology Group (ECOG). Of 16 ER-positive patients, 12 (75%) responded; of 14 ER-negative patients, six (43%) responded (P < 0.05). The two groups did not differ significantly in chemotherapy received, menopausal status, site of predominant disease, stage at diagnosis, or disease-free interval. Response to cytotoxic chemotherapy does not appear to correlate with ER status.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Drug Therapy, Combination
  • Female
  • Humans
  • Prednisone / therapeutic use
  • Prognosis
  • Receptors, Estrogen / metabolism*
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Receptors, Estrogen
  • Prednisone